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Identification of selective protein-protein interaction inhibitors 
using efficient in silico peptide-directed ligand design.  
Andrew M. Beekman,*a Marco M. D. Cominetti,a Samuel J. Walpole,a Saurabh Prabhu,a Maria A. 
O’Connell,a Jesus Anguloa and Mark Searcey*a,b 
The development of protein-protein interaction (PPI) inhibitors with therapeutic value is of increasing importance as the 
first clinical agent has now been approved, but PPIs remain difficult targets for the development of small molecule ligands. 
This article describes a highly efficient approach to the development of inhibitors of the p53/hDMX or hDM2 interaction that 
involves the design of small molecules in silico based upon a peptide/protein structure. The process for molecule design, 
starting from a virtual library of just over 1200 fragments,  led to the eventual synthesis of twenty compounds, of which ten 
bound to either hDM2, hDMX or both in vitro binding assays. This 50% success rate is extremely efficient compared to 
traditional high throughput screening. The identification of two selective hDMX inhibitors from twenty compounds highlights 
this efficiency as, to date, only two other hDMX-selective agents exist in the literature. Preliminary biological studies show 
that 20% of the compounds identified have cellular activity and activate downstream pathways associated with p53 
activation.   
   
Introduction 
Targeting the hDM2 (human double minute 2) p53 protein-
protein interaction (PPI) has been a paradigm for PPI inhibitor 
development in cancer since the discovery of nutlin-3, which is 
currently undergoing clinical trials.1, 2 Although there are many 
studies of p53-hDM2 interaction inhibitors ranging from natural 
products to designed small molecules, the scope of this 
promising strategy has been severely limited by the activity of 
hDMX.3 Despite the highly homologous nature of hDMX to 
hDM2 the two proteins do not perform redundant roles.4, 5 
hDMX can prevent p53 activity by sequestering it, but hDMX 
also enhances the ligase activity of hDM2 towards p53 by 
forming hDM2/hDMX dimers.6 The overexpression of one or 
both of these proteins results in the loss of p53 activity in cells.7 
Therefore, dual hDM2 hDMX inhibitors have become highly 
desirable.  
The development of hDMX selective molecules is also of 
significant importance. It has been shown that direct inhibition 
of hDM2 leads to p53 dependent toxicity in healthy cells.8, 9 
Additionally, the non-redundant roles and common mutual 
exclusivity in cancers suggest selective compounds are useful.10 
There are currently no small molecules that modulate 
hDMX/p53 and exhibit both cell and animal efficacy.11 Two 
compounds have been highlighted which modulate hDMX/p53 
selectively, but are unsuitable for clinical development.8, 9, 12 
Therefore, there is still a demand for chemical probes or leads 
that are selective for hDM2, selective for hDMX or dual hDM2 
hDMX inhibitors. The p53 binding domains of hDM2 and hDMX 
display high structural homology, but differences exist which 
could be exploited.7, 10  
Several approaches to the identification of inhibitors of the p53-
hDM2 and p53-hDMX interaction have been described. Natural 
products such as chlorofusin can be utilised as starting points 
for design.13 Oligobenzamide analogues that mimic the 
interactions of the helical peptide have been described14, 15 and 
helical peptides have been stabilised and shown to have cellular 
activity through the introduction of stapling groups.16 Both high 
throughput screening and computational design against the 
hDM2 target have had varying degrees of success with hit rates 
for screening of around 0.02%. 
We believe these challenging PPIs are excellent targets for the 
exemplification of in silico peptide directed binding, a new 
methodology for identifying selective PPI modulators. Using 
copper(I) catalysed azide-alkyne cycloaddition (CuAAC) click 
chemistry and taking a small commercially available library of 
896 alkynes and 214 azides would require the synthesis of 
191,744 compounds to screen all possible compounds. Using 
these compounds as fragments for screening would need high 
resolution NMR with 15N-labelled protein or high throughout 
crystallography, relatively specialised techniques. Our approach 
has been to exploit the peptidic dual inhibitor Ac-Phe-Met-Aib-
Pmp-6-Cl-Trp-Glu-Ac3c-Leu-NH2 (1) to develop small molecule 
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probes that target hDM217 and hDMX.18 Briefly, the crystal 
structure of 1 bound to both proteins is known (hDMX: PDB ID 
2GV2, hDM2: PDB ID 3FEA). The sequence of the high affinity 
peptide binder is used to generate two smaller peptides with 
reactive azide and alkyne terminals (Figure 1).19 In silico 
screening of the small molecule fragments then allows the 
identification of peptide/small molecule hybrids with restored 
affinity for the target site. The restoration of binding affinity 
implies that the small molecule fragment in some way emulates 
the peptide section it has replaced. The small molecule portion 
of the hybrid hits are then combined through in silico click 
chemistry and rescreened to identify potential small molecules 
with high affinity for the target site. Computational modelling is 
used to perform the entire peptide directed binding process, 
identifying small molecules to be prepared.  This use of virtual 
design in peptide directed binding further improves the rapid 
and economic nature of this process, identifying compounds 
not highlighted by experimental peptide directed binding.19 
Herein, we demonstrate that this approach led to the synthesis 
of twenty small molecules of which ten bound to hDM2 or 
hDMX, representing a 50% success rate. Furthermore, one 
compound was selective for hDMX both in vitro and in tissue 
culture, outperforming previously reported selective 
modulators. 
Results 
In silico peptide directed binding identifies candidate small 
molecule hDM2/X binders 
Peptide 1 binds with high affinity to both hDM2 and hDMX, 
which allows its exploitation to develop small molecule dual 
inhibitors as both chemical probes and potential therapeutic 
lead molecules. In order to identify small molecules to be 
synthesised and evaluated against hDM2 and hDMX the crystal 
structures for the peptide 8-mer 1 bound to hDM2 (PDB ID: 
2GV2)17 (Figure 2A) and hDMX (PDB ID: 3FEA)18 were edited to 
identify small molecule fragments that emulate a section of the 
8 mer (Figure 2B and 2C). The peptide was split, Phe-Met-Aib-
Pmp-propargyl glycine and azidoacetamide-6-Cl-Trp-Glu-Ac3c-
Leu (Figure 1B), allowing two key binding residues to be present 
in both smaller peptides (Phe and Pmp, 6-Cl-Trp and Leu). The 
site left vacant by the removed peptide fragment represents a 
more tractable binding site for a small molecule. Covalent 
docking was then performed simulating the Huisgen 1,3-dipolar 
cycloaddition (see SI, pg 6), with the commercially available 
library of alkynes or azides (SI, pg 12). The semi-peptide was 
held in place with flexibility in the reactive terminal and the final 
residue, allowing for the possibility that the added small 
molecule fragment is held in the correct orientation for binding. 
The results were scored and ranked20 and the top ten azides and 
top ten alkynes that were synthetically viable were used to 
generate one hundred virtual triazoles. The generated triazoles 
were then induced-fit docked to the protein, scored and ranked  
 
Figure 1. Concept of peptide directed binding utilised in this work with in silico 
methods to improve the rapid and economic nature of finding new PPI modulators. 
Peptide 1 binds to hDM2/X, and is separated in to two smaller peptides with no 
appreciable binding despite having two key residues each. Azide-alkyne 
cycloaddition (AAC) identifies small molecule fragments which restore binding 
affinity. The identified small molecule fragments can be combined to generate a 
small molecule substitute for the initial peptide. 
to identify the top ten small molecules that bound in silico with 
high affinity to each protein and that would be synthesised 
(Figure 2D).21 The identified triazole small molecules are likely 
to bind with the same binding elements as identified by the 
hybrid, but may sit in a slightly altered orientation to allow for 
tighter binding. This process was carried out for both hDM2 and 
hDMX and as such twenty small molecule triazoles were 
synthesised following published procedures with CuSO4 and 
sodium ascorbate in a tBuOH/H2O mix, followed by purification 
by reverse phase HPLC (See SI pg. 9 for all synthesised 
compounds).13 
 
Identified small molecules selectively modulate the p53-hDM2/X 
PPIs 
It was expected that some of these molecules would display 
selectivity for the target used in their design, but inevitably dual 
modulators would be identified due to the homogeneity of the 
hDM2/X binding sites and the use of the same peptide 1. The 
synthesised compounds were first analysed with competitive 
fluorescence anisotropy (FA) assays. A FAM tagged p4 peptide22, 
23 was used as the fluorescently tagged peptide for both hDM2, 
reported previously,13 and hDMX. The wild-type p53 peptide 
(residues 15-27) was employed as a positive control and an 
indication that the FA assays were performing adequately. Of 
the twenty compounds synthesised, 50% demonstrated binding 
in the FA assays to either hDM2 or hDMX, with IC50 values less 
than 100 µM (Table 1). Strikingly, one compound displayed 
significant selectivity for hDMX over hDM2 (5), while overall 
40% of compounds designed for hDMX modulated the hDMX 
interaction (2, 3, 4, 5). Two of these compounds, 2 and 3, had  
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Table 1. IC50 values for inhibition of the binding of FAM-p4 to hDM2 and hDMX of small molecules.[a] A green background indicates the compound was 
designed for and was selective to the same protein. Yellow indicates the compound is a dual inhibitor. A red background indic ates the compound was 
designed for one protein but was selective for the other protein. 
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 [a]IC50 values determined by non-linear regression of at least three independent experiments (see SI, pg 10). Errors are 95% confidence intervals (CI). 
Fmoc, 9-fluorenylmethylcarbony
an IC50 in the tens of nanomolar range. Of the compounds 
designed for hDM2, 50% demonstrated the ability to modulate 
the hDM2 PPI (6, 7, 8, 9, 10), with three showing selectivity for 
hDM2 over hDMX (7, 8, 9). Interestingly, one of the compounds 
designed for hDM2 (11) had affinity for hDMX but no 
appreciable binding to hDM2. To confirm selectivity, these 
compounds were analysed in other PPI FA assays routinely 
utilised in our lab. Pleasingly, compounds 2-11 demonstrated no 
appreciable binding at 100 µM towards the PPIs Mcl-1/Noxa, 
Bcl-2/Bid19 and Nrf2/Keap1,24 despite similarities to compounds 
reported to bind to these PPIs.  
The compounds that exhibited binding in the FA assay were 
validated with differential scanning fluorimetry (DSF).25 
Compounds displayed the ability to increase the melting 
temperature of proteins compared to a vehicle control (see SI, 
pg. 41).26 Thermal stability was demonstrated using the 
hydrophobic dye Sypro orange, mimicking the observed FA 
assay results (see SI, pg. 40).  
 
Use of STD NMR indicates that compounds bind in the p53 binding 
site of hDM2/X 
 To provide structural details of the binding of these compounds 
in the p53 binding site, we employed an STD NMR initial growth-
rates approach to identify the binding mode and the 
interactions with the binding grooves of hDM2 and hDMX.27-29 
Compound 4 was chosen for analysis by STD NMR because of its 
solubility in aqueous buffer and its relatively weak binding to 
both hDM2 and hDMX, allowing the binding kinetics to fall 
within the fast-exchange conditions necessary for STD NMR. 
This criteria precludes tighter binders (2 & 3) from being 
analysed with this technique. Compound 4 displayed STD 
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signals in the presence of either hDM2 or hDMX, indicating 
binding to both proteins.  
 
Figure 2. Examples of competitive-displacement assays of small molecules 
towards a selection of PPIs. Compounds 5 and 10 used to exemplify the titration 
of compounds towards the hDMX/p53, hDM2/p53, Mcl-1/NOXA, Bcl-2/Bid and 
Nrf2/Keap1 interactions. Dose response curves can be seen for 5 towards hDMX, 
and for 10 towards hDMX and hDM2, with no competitive binding towards any 
other PPIs observed. 
Additionally, the ligand binding epitope of compound 4 was 
mapped using the STD-NMR initial growth rates method (SI, pg 
15). In order to gain some structural information docking 
calculations were used to identify a binding pose. We were able 
to validate the binding pose within the hDM2 binding groove 
using CORCEMA-ST,30 which calculates theoretical STD 
intensities based on a given 3D model complex. The NOE R-
factor between the experimental and theoretical STD intensifies 
was 0.17, indicating good agreement. Interestingly, preliminary 
CORCEMA-ST trials of 4 binding to hDMX suggested the 
formation of oligomers. Dimerization induced by structurally 
similar compounds has been observed previously,8 and suggests 
a possible selective binding mode which could be exploited for 
hDMX modulation. Figure 3 displays the binding pose of 4 to 
hDM2 demonstrating tight binding of the fluorinated aryl ring in 
the pocket vacated by chlorotryptophan of 1. This 
STD/CORCEMA-ST validated binding pose, along with the 
binding affinities determined by the competitive fluorescence 
anisotropy assay indicate these compounds are binding in the 
p53 binding groove. The identified binding epitope places the 
fluorine atom in the same pocket as that occupied by the 
chlorine atom of the Cl-Trp in 1. This same pocket also exists in 
the hDMX binding site and may explain the improved binding of 
the fluoroaryl group (2, 10 & 11 compared to S8, S2 & S9). 
 
 
Figure 3. Binding pose of 4 (purple) to hDM2 in the p53 binding site determined 
by CORCEMA-ST, with an overlay of peptide 1 (orange) showing the binding 
residues of Leu and Cl-Trp. The surface of hDM2 is cut along the plane of the 
centroid of the aromatic rings of compound 4. 
Compounds inhibit cancer cell growth in a selective fashion 
Compounds that had activity in the FA assay were examined for 
their ability to inhibit cell growth and affect metabolism in an 
array of cancer cell lines that demonstrate varying expressions 
of the p53 and hDM2/X proteins. The human cancer cell lines 
A549,31 HCT1163, 31 and MCF-731 express both hDM2 and hDMX, 
SJSA-1 is hDM2 dependent11 and JEG3 is hDMX dependent.3 All 
cell lines express wild type p53. Gratifyingly, 10% of the 
prepared compounds demonstrated the ability to inhibit cell 
growth. Compound 10, which was shown to bind to both hDM2 
and hDMX, had activity towards cell lines that are dependent on 
hDMX, dependent on hDM2 or dependent on both, as expected 
(Table 2). Compound 5, which showed selectivity for hDMX over 
hDM2, demonstrated activity towards the hDMX dependent 
JEG3, but not towards the hDM2 dependent SJSA-1, a further 
suggestion of selectivity of 5 for hDMX. The remaining 
compounds did not demonstrate activity in the MTS assay, 
perhaps due to issues with cell penetration. Alterations to the 
in silico screening process are currently underway to increase 
the output of compounds with desirable characteristics, such as 
cell permeability. 
Table 2. Cell growth inhibition of compounds which demonstrated activity towards 














16.2        
± 0.06 
20.5        
± 0.07 
29.8        
± 0.13 
35.5        
± 0.10 
10 
30.0        
± 2.29 
65.7        
± 0.22 
>100 >100 
38.1        
± 0.03 
[a]IC50 values determined by non-linear regression of at least three 
experiments (see SI, pg 13). Errors are the transformed greater extreme of the 
standard error. 
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Figure 4. A) A549 and JEG-3 cells were treated with vehicle (DMSO), positive control (staurosporine, STS), 5 and 10 at 100 µM and 50 µM for 6 hr, 4 hr and 2 hr at 
37 °C. Treatment with Caspase-Glo 3/7 reagent (Promega) allowed for the monitoring of the cleavage of pro-luminescent substrate by caspase 3/7. Data are mean ± 
SEM for at least n = 3. RLU – relative luminescent units. STS – staurosporine. B) JEG-3 cells were treated with vehicle (DMSO), 5 and 10 at 100 µM for 6 hr at 37 °C, 
and transcriptional upregulation of p53, hDM2, p21 and MIC-1 was evaluated by qPCR analysis. 18S was used as a control. Y-axis is the mRNA-fold induction vs the 
vehicle control (DMSO). All p values were less than 0.05 when compared to the vehicle. 
Compounds induce events downstream of p53 activation 
To ascertain whether compounds 5 and 10 were inducing p53 
related cell death we examined the induction of apoptosis with 
a caspase 3/7 activation assay. A549 and JEG-3 cells were 
treated with vehicle (DMSO), positive control (staurosporine), 5 
and 10. Cleavage of the DEVD sequence was monitored to 
observe caspase 3/7 activity. Activation of caspase 3/7 was 
observed for both 5 and 10 in line with the observed IC50 values 
(Figure 4A). The transcriptional activation of targets 
downstream of p53 was examined with quantitative PCR 
(qPCR).3 JEG-3 cells were treated with vehicle control, 5 and 10 
for 6 hr at 37 °C, followed by RNA isolation, reverse 
transcription, and qPCR analysis of the obtained cDNA using the 
primers of downstream p53 targets p53, hDM2, p21 and MIC-1. 
Both compounds 5 and 10 significantly increased the expression 
of each of the target genes when compared to the vehicle 
control (Figure 4B). 
Virtual peptide directed binding was employed to identify new 
modulators of p53/hDM2 and p53/hDMX. This use of 
computational peptide directed binding represents a 
complementary method to identify PPI modulators in a rapid 
and economic manner. Twenty compounds were prepared, ten 
designed for hDM2 and ten designed for hDMX, and 50% of the 
compounds were found to modulate the PPI. This hit rate is a 
significant improvement compared to recent studies which 
utilise a chemical  array (0.04%)32 and high-throughput screen 
(0.07%).33 Applying peptide directed binding to the p53-
hDM2/X PPIs has identified new scaffolds for modulating these 
PPIs, which have excellent lead like features.34 Importantly, this 
process has identified selective inhibitors for both hDM2 and 
hDMX, despite the high structural homology of the binding sites 
of these proteins. Only two small molecules have been 
previously reported which selectively modulate the p53-hDMX 
PPI, highlighting the power of this technique. Virtual peptide 
directed binding has identified compounds that interact with 
the p53 binding site of hDM2 and hDMX, supported by activity 
in competitive fluorescence anisotropy assays and, more 
significantly, quantitative STD NMR analysis. A subset of the 
identified modulators was shown to have activity towards 
cancer cell lines that are known to have dependence on hDM2, 
hDMX or both, and these compounds were shown to induce p53 
activation downstream events.  
Discussion 
The deployment of in silico peptide directed binding has 
demonstrated an extraordinarily high hit rate for new PPI small 
molecule modulators of the p53 hDM2/X interaction. Perhaps 
more interestingly, this process has identified new binding 
motifs for these PPIs, as well as highlighting selective scaffolds 
for hDMX, a notoriously challenging task.35, 36 The nature of 
peptide directed binding provides structure activity relationship 
information without producing specific modifications. The 
fluoroaryl group shows enhanced binding to hDMX, and the 2,4-
difluoroaryl compound may offer selectivity for hDMX (i.e. 5 
and 11). The Fmoc azoalanine drives binding to hDM2, a 
phenomenon we have shown previously,13 but does not 
guarantee binding (S1 – see SI, pg. 9). The presence of the sugar 
moiety imparts potent binding, but again does not guarantee it 
(S8). Despite the FP and DSF results supporting tight binding, 
the hydrophilic sugar moiety raises concerns about compounds 
2 and 3 as leads, as the p53 binding site is known to be 
hydrophobic. Docking suggested the polar sugar occupying the 
Phe binding pocket of 1 (See SI, pg 14), but docking results 
should be interpreted with caution. Modifying the sugar with 
nonpolar protecting groups reduces potency, but affinity is still 
observed (i.e. 10 and 11), suggesting key binding moieties may 
still be available. Investigation of 2 and 3 as leads is ongoing. The 
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in silico calculations highlighted the zidovudine structure (azide 
section of 9) as a likely potent binder, but experimentally 
resulted in a poor hit rate, perhaps highlighting modifications to 
be made in compound selection process or docking calculations 
(see SI, pg 9). 
The compounds identified which selectively modulate the p53-
hDMX interaction outperform the two selective molecules 
reported in the literature. The first known selective binder of 
hDMX – SJ-172550 – was demonstrated to bind with less affinity 
to hDMX than p53. Both 5 and 11 demonstrate greater binding 
affinity to hDMX than p53 (SI, pg 10).35 Additionally, the cellular 
activity of these compounds is reported in the millimolar range, 
with our compounds demonstrating at least two orders of 
magnitude improvement. SJ-172550 is also known to not be a 
competitive binder, but rather induces a conformational change 
through covalent bond formation, which does not exist in a 
reducing environment.37 Unfortunately, this limits the value of 
SJ-172550 as a lead candidate.  
CTX1, the second small molecule shown to have selectivity for 
hDMX, has not been validated in in vitro protein assays, with 
this compound being identified through a cellular screen.9 CTX1 
demonstrated IC50 values in the tens to hundreds of micromolar 
range. Compound 5 possesses slightly improved potency, but 
has other important advantages. CTX1 is an acridine based 
molecule, known to bind to DNA, and act as a PAIN molecule. 
This characteristic makes CTX1 unusable in many light based 
assays, such as fluorescence, due to interference. It is also 
unknown whether CTX1 is a competitive inhibitor of p53 or acts 
through some other mechanism (some suggestion the CTX1 
mode of action overlaps with the action of 9-aminoacridine),9 
making its use as a chemical tool limited. 
SJ-172550 was found as one of three hits in a library of 295,848 
compounds.35 CTX1 came from a screen of over 20,000 
compounds.9 In this instance we have prepared twenty 
molecules and identified two selective p53-hDMX modulators. 
The true value of the significant advance in the improvement of 
success rate we have demonstrated here is the power of 
peptide directed binding to allow researchers in academia and 
the pharmaceutical industry, chemistry and biology to quickly 
and cheaply develop modulators for the protein-protein 
interaction they wish to target. The need for enormous libraries 
of molecules and expensive high throughput screening facilities 
is not necessary for the identification of small molecule 
modulators, as has been the case for so many challenging 
targets. 
Notably, the compounds prepared are unoptimised but still 
display strong activity in the fluorescence anisotropy assay and 
low micromolar cellular activity, highlighting the rapid ability of 
peptide directed binding to identify selective chemical probes. 
Conclusions 
This work has exemplified the power of peptide directed 
binding to rapidly identify small molecule PPI modulators, at a 
high hit rate, that show selectivity for challenging targets. This 
method complements experimental peptide directed binding 
and is expected to be readily applied to other PPIs such as 14-3-
3/tau, bromodomains or Nrf2/Keap1. 
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